Sangamo Therapeutics Inc

Research Sangamo Therapeutics Inc (SGMO) on Bullrun: market cap USD 30.66M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 30.66M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 39.55M-USD 122.93M-USD 97.31Mn/a-0.44USD 20.95MUSD 26.80M-USD 14.27M
FY2024USD 57.80M-USD 97.94M-USD 67.41Mn/a-0.49USD 41.92MUSD 30.57MUSD 22.77M
FY2023USD 176.23M-USD 257.83M-USD 246.00Mn/a-1.48USD 45.20MUSD 38.10MUSD 82.89M
FY2022USD 111.30M-USD 192.28M-USD 243.80Mn/a-1.25USD 100.44MUSD 41.53MUSD 294.96M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-07-02USD 30.66Mn/an/an/a
20252025-12-31USD 147.29Mn/an/an/a
20242024-12-31USD 217.09Mn/an/an/a
20232023-12-29USD 95.77Mn/an/an/a
20222022-12-30USD 514.58Mn/an/an/a
20212021-12-31USD 1.09Bn/an/an/a

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Sangamo Therapeutics Inc's market cap?

Sangamo Therapeutics Inc's market capitalization is USD 30.66M.

What does Sangamo Therapeutics Inc do?

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.